Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cost of Revenue	46.89	41.76	26.45	42.33	38.96	26.34
Gross Profit	-46.89	-41.76	-26.45	-42.33	-38.96	-26.34
Selling, General & Admin	36.09	29.94	26.67	20.74	12.77	9.97
Operating Expenses	36.09	29.94	26.67	20.74	12.77	9.97
Operating Income	-82.99	-71.7	-53.13	-63.07	-51.73	-36.31
Interest Expense	-3.16	-3.16	-2.53	-1.49	-0.94	-1.76
Interest & Investment Income	0.77	0.91	0.97	-	-	-
Earnings From Equity Investments	-0.14	-0.1	-0.01	-0.05	-0.05	-
Other Non Operating Income (Expenses)	41.47	1.15	0.05	0.47	-0.45	1.98
EBT Excluding Unusual Items	-44.04	-72.91	-54.65	-64.14	-53.16	-36.09
Asset Writedown	-	-	-	-	-	-0.53
Other Unusual Items	-2.77	-2.46	-4.33	-1.91	-	-1.9
Pretax Income	-46.81	-75.36	-58.98	-66.05	-53.16	-38.51
Income Tax Expense	0	0	0	0	0	-3.27
Earnings From Continuing Operations	-46.81	-75.37	-58.98	-66.05	-53.16	-35.24
Net Income	-46.81	-75.37	-58.98	-66.05	-53.16	-35.24
Preferred Dividends & Other Adjustments	-	-	-	-	-	13.63
Net Income to Common	-46.81	-75.37	-58.98	-66.05	-53.16	-48.87
Shares Outstanding (Basic)	21	19	13	11	8	4
Shares Outstanding (Diluted)	21	19	13	11	8	4
Shares Change (YoY)	65.29%	48.29%	17.96%	38.91%	110.43%	298.84%
EPS (Basic)	-2.19	-4.06	-4.72	-6.23	-6.96	-13.47
EPS (Diluted)	-2.19	-4.06	-4.72	-6.23	-6.96	-13.47
Free Cash Flow	-66.73	-68.79	-42.97	-56.67	-54.25	-31.79
Free Cash Flow Per Share	-3.13	-3.71	-3.44	-5.34	-7.11	-8.76
EBITDA	-82.87	-71.59	-53.08	-62.87	-51.46	-35.76
D&A For EBITDA	0.11	0.11	0.04	0.2	0.26	0.55
EBIT	-82.99	-71.7	-53.13	-63.07	-51.73	-36.31

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q